BACKGROUND: Quality of life in prostate cancer patients with clinically localized disease has become the focus of increasing attention over the past decade. However, few instruments have been developed and validated to assess quality of life specifically in this patient population. OBJECTIVE: The purpose of this investigation was to create a comprehensive, multi-scale quality of life instrument that can be tailored to the needs of the clinician/investigator in multiple settings. DESIGN, SUBJECTS, AND MEASURES: Patients diagnosed with clinically localized prostate cancer were mailed a questionnaire consisting of new and previously validated quality of life items and ancillary scales. Data from returned questionnaires were analyzed and used to create a multiscale instrument that assesses the effects of treatment and disease on urinary, sexual, and bowel domains, supplemented by a scale assessing anxiety over disease course/effectiveness of treatment. The instrument was then mailed to a second sample of prostate cancer patients once and then again two weeks later to assess test retest reliability. To assess feasibility in clinical settings, the instrument was self-administered to a third patient sample during a urology clinic visit. RESULTS: All scales exhibited good internal consistency and test retest reliability, convergent and discriminant validity, and significant correlations with disease specific, generic health-related, and global measures of quality of life. Men with greater physiologic impairment reported more limitations in role activities and more bother. Scales were also able to differentiate patients undergoing different therapies. All scales exhibited negligible correlations with a measure of socially desirable responding. Additionally, the instrument proved feasible when used as a self-administered questionnaire in a clinical setting. CONCLUSIONS: The current instrument possesses brief multi-item scales that can be successfully self-administered in multiple settings. The instrument is flexible, relatively quick, psychometrically reliable and valid, and permits a more comprehensive assessment of patients' quality of life.
BACKGROUND: Quality of life in prostate cancerpatients with clinically localized disease has become the focus of increasing attention over the past decade. However, few instruments have been developed and validated to assess quality of life specifically in this patient population. OBJECTIVE: The purpose of this investigation was to create a comprehensive, multi-scale quality of life instrument that can be tailored to the needs of the clinician/investigator in multiple settings. DESIGN, SUBJECTS, AND MEASURES: Patients diagnosed with clinically localized prostate cancer were mailed a questionnaire consisting of new and previously validated quality of life items and ancillary scales. Data from returned questionnaires were analyzed and used to create a multiscale instrument that assesses the effects of treatment and disease on urinary, sexual, and bowel domains, supplemented by a scale assessing anxiety over disease course/effectiveness of treatment. The instrument was then mailed to a second sample of prostate cancerpatients once and then again two weeks later to assess test retest reliability. To assess feasibility in clinical settings, the instrument was self-administered to a third patient sample during a urology clinic visit. RESULTS: All scales exhibited good internal consistency and test retest reliability, convergent and discriminant validity, and significant correlations with disease specific, generic health-related, and global measures of quality of life. Men with greater physiologic impairment reported more limitations in role activities and more bother. Scales were also able to differentiate patients undergoing different therapies. All scales exhibited negligible correlations with a measure of socially desirable responding. Additionally, the instrument proved feasible when used as a self-administered questionnaire in a clinical setting. CONCLUSIONS: The current instrument possesses brief multi-item scales that can be successfully self-administered in multiple settings. The instrument is flexible, relatively quick, psychometrically reliable and valid, and permits a more comprehensive assessment of patients' quality of life.
Authors: J A Talcott; P Rieker; J A Clark; K J Propert; J C Weeks; C J Beard; K I Wishnow; I Kaplan; K R Loughlin; J P Richie; P W Kantoff Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: Peter Chang; Konrad M Szymanski; Rodney L Dunn; Jonathan J Chipman; Mark S Litwin; Paul L Nguyen; Christopher J Sweeney; Robert Cook; Andrew A Wagner; William C DeWolf; Glenn J Bubley; Renee Funches; Joseph A Aronovitz; John T Wei; Martin G Sanda Journal: J Urol Date: 2011-07-23 Impact factor: 7.450
Authors: Patrick O Monahan; Victoria Champion; Susan Rawl; R Brian Giesler; Barbara Given; Charles W Given; Debra Burns; Silvia Bigatti; Kristina M Reuille; Faouzi Azzouz; Jingwei Wu; Michael Koch Journal: Qual Life Res Date: 2006-11-08 Impact factor: 4.147
Authors: J I Arraras; E Villafranca; F Arias de la Vega; P Romero; M Rico; M Vila; G Asín; V Chicata; M A Domínguez; N Lainez; A Manterola; E Martínez; M Martínez Journal: Clin Transl Oncol Date: 2009-03 Impact factor: 3.405
Authors: Catherine E Lovegrove; Vincenzo Ficarra; Francesco Montorsi; James N'Dow; Andrea Salonia; Suks Minhas Journal: Int J Impot Res Date: 2019-12-13 Impact factor: 2.896
Authors: Richard J Rebello; Christoph Oing; Karen E Knudsen; Stacy Loeb; David C Johnson; Robert E Reiter; Silke Gillessen; Theodorus Van der Kwast; Robert G Bristow Journal: Nat Rev Dis Primers Date: 2021-02-04 Impact factor: 52.329